Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab

Sore Throat (Patient Counselling Guide)

16 Dec 2016
A sore throat is a condition characterized by discomfort, pain, or scratchiness in the throat causing swallowing to be difficult and painful. There is often dryness and redness of the throat as well as a raspy feeling when a person has a sore throat. It is often caused by a virus, but in children and adolescents, it may be due to a streptococcal (bacterial) infection. An untreated streptococcal throat infection may pose a risk of rheumatic fever, which may lead to a fatal condition called rheumatic heart disease (RHD). Other causes of sore throat may include exposure to environmental pollutants and respiratory irritants (e.g., cigarette smoke), dryness of air, prolonged screaming and backflow of stomach acids up into the back of the throat. Alcoholic beverages and spicy foods may also cause local irritation of the throat.

* Click below to view Patient Counselling Guide

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab